Literature DB >> 21507930

FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors.

Zebin Wang1, Hyun Jung Park, Janai R Carr, Yi-ju Chen, Yu Zheng, Jing Li, Angela L Tyner, Robert H Costa, Srilata Bagchi, Pradip Raychaudhuri.   

Abstract

Malignant neuroblastomas contain stem-like cells. These tumors also overexpress the Forkhead box transcription factor FoxM1. In this study, we investigated the roles of FoxM1 in the tumorigenicity of neuroblastoma. We showed that depletion of FoxM1 inhibits anchorage-independent growth and tumorigenicity in mouse xenografts. Moreover, knockdown of FoxM1 induces differentiation in neuroblastoma cells, suggesting that FoxM1 plays a role in the maintenance of the undifferentiated progenitor population. We showed that inhibition of FoxM1 in malignant neuroblastoma cells leads to the downregulation of the pluripotency genes sex determining region Y box 2 (Sox2) and Bmi1. We provided evidence that FoxM1 directly activates expression of Sox2 in neuroblastoma cells. By using a conditional deletion system and neurosphere cultures, we showed that FoxM1 is important for expression of Sox2 and Bmi1 in the mouse neural stem/progenitor cells and is critical for its self-renewal. Together, our observations suggested that FoxM1 plays an important role in the tumorigenicity of the aggressive neuroblastoma cells through maintenance of the undifferentiated state.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21507930      PMCID: PMC3771352          DOI: 10.1158/0008-5472.CAN-10-4087

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment.

Authors:  Galina A Gusarova; I-Ching Wang; Michael L Major; Vladimir V Kalinichenko; Timothy Ackerson; Vladimir Petrovic; Robert H Costa
Journal:  J Clin Invest       Date:  2006-12-14       Impact factor: 14.808

2.  Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.

Authors:  Qun Wang; Sharon Diskin; Eric Rappaport; Edward Attiyeh; Yael Mosse; Daniel Shue; Eric Seiser; Jayanti Jagannathan; Suzanne Shusterman; Manisha Bansal; Deepa Khazi; Cynthia Winter; Erin Okawa; Gregory Grant; Avital Cnaan; Huaqing Zhao; Nai-Kong Cheung; William Gerald; Wendy London; Katherine K Matthay; Garrett M Brodeur; John M Maris
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

3.  The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer.

Authors:  Yuichi Yoshida; I-Ching Wang; Helena M Yoder; Nicholas O Davidson; Robert H Costa
Journal:  Gastroenterology       Date:  2007-01-25       Impact factor: 22.682

4.  Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner.

Authors:  Hongjuan Cui; Jun Ma; Jane Ding; Tai Li; Goleeta Alam; Han-Fei Ding
Journal:  J Biol Chem       Date:  2006-09-18       Impact factor: 5.157

5.  Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice.

Authors:  Tanya V Kalin; I-Ching Wang; Timothy J Ackerson; Michael L Major; Carol J Detrisac; Vladimir V Kalinichenko; Alexander Lyubimov; Robert H Costa
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

6.  The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer.

Authors:  Il-Man Kim; Timothy Ackerson; Sneha Ramakrishna; Maria Tretiakova; I-Ching Wang; Tanya V Kalin; Michael L Major; Galina A Gusarova; Helena M Yoder; Robert H Costa; Vladimir V Kalinichenko
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

7.  Bmi-1 is essential for the tumorigenicity of neuroblastoma cells.

Authors:  Hongjuan Cui; Bo Hu; Tai Li; Jun Ma; Goleeta Alam; William T Gunning; Han-Fei Ding
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

Review 8.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

9.  Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell.

Authors:  Loen M Hansford; Amy E McKee; Libo Zhang; Rani E George; J Ted Gerstle; Paul S Thorner; Kristen M Smith; A Thomas Look; Herman Yeger; Freda D Miller; Meredith S Irwin; Carol J Thiele; David R Kaplan
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

10.  Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.

Authors:  Socorro M Rodriguez-Pinilla; David Sarrio; Gema Moreno-Bueno; Yolanda Rodriguez-Gil; Miguel A Martinez; Lucia Hernandez; David Hardisson; Jorge S Reis-Filho; Jose Palacios
Journal:  Mod Pathol       Date:  2007-03-02       Impact factor: 7.842

View more
  49 in total

1.  FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells.

Authors:  Ai-Hua Gong; Ping Wei; Sicong Zhang; Jun Yao; Ying Yuan; Ai-Dong Zhou; Frederick F Lang; Amy B Heimberger; Ganesh Rao; Suyun Huang
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

2.  Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer.

Authors:  Vaibhav Chand; Akshay Pandey; Dragana Kopanja; Grace Guzman; Pradip Raychaudhuri
Journal:  Mol Cancer Res       Date:  2019-02-27       Impact factor: 5.852

3.  Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.

Authors:  Liang Chen; Jingxuan Pan
Journal:  Br J Pharmacol       Date:  2017-06-18       Impact factor: 8.739

Review 4.  Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.

Authors:  Fung Zhao; Eric W-F Lam
Journal:  Front Med       Date:  2012-11-03       Impact factor: 4.592

5.  Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma.

Authors:  Zebin Wang; Yu Zheng; Hyun Jung Park; Jing Li; Janai R Carr; Yi-ju Chen; Megan M Kiefer; Dragana Kopanja; Srilata Bagchi; Angela L Tyner; Pradip Raychaudhuri
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

6.  FoxM1 regulates mammary luminal cell fate.

Authors:  Janai R Carr; Megan M Kiefer; Hyun Jung Park; Jing Li; Zebin Wang; Joel Fontanarosa; Danielle DeWaal; Dragana Kopanja; Elizaveta V Benevolenskaya; Grace Guzman; Pradip Raychaudhuri
Journal:  Cell Rep       Date:  2012-06-07       Impact factor: 9.423

7.  Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.

Authors:  Dragana Kopanja; Akshay Pandey; Megan Kiefer; Zebin Wang; Neha Chandan; Janai R Carr; Roberta Franks; Dae-Yeul Yu; Grace Guzman; Ajay Maker; Pradip Raychaudhuri
Journal:  J Hepatol       Date:  2015-03-28       Impact factor: 25.083

8.  Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Authors:  Julieann Rader; Mike R Russell; Lori S Hart; Michael S Nakazawa; Lili T Belcastro; Daniel Martinez; Yimei Li; Erica L Carpenter; Edward F Attiyeh; Sharon J Diskin; Sunkyu Kim; Sudha Parasuraman; Giordano Caponigro; Robert W Schnepp; Andrew C Wood; Bruce Pawel; Kristina A Cole; John M Maris
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

9.  Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex.

Authors:  Hacer Guvenc; Marat S Pavlyukov; Kaushal Joshi; Habibe Kurt; Yeshavanth K Banasavadi-Siddegowda; Ping Mao; Christopher Hong; Ryosuke Yamada; Chang-Hyuk Kwon; Deepak Bhasin; Somsundaram Chettiar; Gaspar Kitange; In-Hee Park; Jann N Sarkaria; Chenglong Li; Mihail I Shakhparonov; Ichiro Nakano
Journal:  Clin Cancer Res       Date:  2012-12-18       Impact factor: 12.531

Review 10.  FOX(M1) news--it is cancer.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.